Anna Protopapas

Anna Protopapas

Chairman at NUVALENT, INC.

Net worth: 948 250 $ as of 2026-05-30

61 year
Health Technology
Consumer Services
Process Industries

Profile

Ms. Anna Protopapas is a Chief Executive Officer & Director at Flare Therapeutics, Inc. and an Independent Chairman at Nuvalent, Inc. She is on the Board of Directors at Flare Therapeutics, Inc. Ms. Protopapas was previously employed as an Independent Director by Dicerna Pharmaceuticals, Inc., an Independent Director by ARIAD Pharmaceuticals, Inc., an Executive VP-Global Business Development by Takeda Pharmaceutical Co., Ltd., a Head-Global Business Development by Takeda Pharmaceuticals International, Inc., and a President & Chief Executive Officer by Takeda Oncology Co. She also served on the board at Bioverativ, Inc., Mersana Therapeutics, Inc. and Ensemble Therapeutics Corp.
She received her undergraduate degree from Princeton University, a graduate degree from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-06-15 8,590 ( 0.01% ) 948 250 $ 2026-05-30
2026-01-05 0 ( -.--% ) - $ 2025-12-30

Anna Protopapas active positions

CompaniesPositionStart
NUVALENT, INC. Chairman 2022-03-29
Chief Executive Officer 2026-06-29

Former positions of Anna Protopapas

CompaniesPositionEnd
MERSANA THERAPEUTICS Chief Executive Officer 2023-09-09
DICERNA PHARMACEUTICALS, INC. Director/Board Member 2021-06-02
BIOVERATIV INC Director/Board Member 2018-03-07
ARIAD PHARMACEUTICALS, INC. Director/Board Member 2017-01-15
Corporate Officer/Principal 2014-09-30
See the detail of Anna Protopapas's experience

Training of Anna Protopapas

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

83

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies13

Health Technology

Health Technology

Process Industries

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Commercial Services

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Anna Protopapas